SURVYR

ABBV

AbbVie Inc.
$286.42
+$0.03 (0.01%)Oct 28 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-14%-2%+9%+20%+32%Oct 2025Oct 2026Apr 202652w high $291.4052w low $190.75
ABBVSPY
Wall St. Highest PT $325.00 (+13.5%) Wall St. Avg PT $283.19 (-1.1%)
$195$230$265$300$335POC $218Hi $325Avg $283
Underwater Drawdown %Max DD -15.7%Current -0.9%
0.0%-15.7%
Relative Strength vs SPY+15.4% vs SPYOutperforming
+21%0%-21%
1W
+$1.62 (0.57%)
1M
+$21.77 (8.22%)
3M
+$24.73 (9.45%)
6M
+$85.21 (42.35%)
YTD
+$64.57 (29.11%)
1Y
+$65.49 (29.64%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
29 analysts · mean score 1.70
1 = Strong Buy · 5 = Sell
Strong Buy724%
Buy1655%
Hold517%
Underperform00%
Sell13%
Wall Street consensus
Analyst price targets
Current price$286.42
Average target$283.19
−$3.23 (−1.1%) downsideaverage target vs current price
CurrentAverageMedian
Low$200.00
Median$288.00
High$325.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-23 · Goldman Sachs reiterated Neutral on ABBV
Reiterated
2026-10-21 · Barclays reiterated Overweight on ABBV
Reiterated
2026-10-13 · RBC Capital reiterated Outperform on ABBV
Reiterated
2026-10-09 · UBS reiterated Neutral on ABBV
Reiterated
2026-10-09 · Guggenheim reiterated Buy on ABBV
Reiterated
2026-10-08 · JP Morgan reiterated Overweight on ABBV
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$506.1B
P/E (last 12 months)80.7
P/E (next 12 months, estimated)17.7
52-week range$190.75 – $291.40
Revenue growth (latest quarter vs a year ago)+10.2%
Dividend yield2.41%
Analyst consensusBuy (27)
Average analyst price target$283.19 (-1%)

What they do

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma.

Healthcare · Drug Manufacturers - General
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
Not enough data yet
–
12-1 return: –
Percentile within its GICS sector across the S&P 1500.
Growth
60th percentile in sector
B-
Revenue growth (YoY): +10.2%
Percentile within its GICS sector across the S&P 1500.
Value
45th percentile in sector
C
Forward E/P: 5.7% · EBITDA/EV: 5.4%
Percentile within its GICS sector across the S&P 1500.
Profitability
59th percentile in sector
B-
Profit margin: +9.8% · Return on equity: –
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 222 of 499 · 12-month momentum 14.2%
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 67 of 589 · 12-month momentum 18.5%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

ABBV earningsNext report in 2 days
Next report · quarter Sep 2026
Fri Oct 30, 2026Before the open
EPS consensus$3.77 range $3.61–$3.86
Revenue consensus$17.3B 21 analysts
Last 4 quarters · EPS vs estimate
Jul 31, 2026$3.65est $3.61+1.1%Above estimates
Apr 29, 2026$2.65est $2.67−0.8%In line with estimates
Feb 4, 2026$2.71est $2.65+2.2%Above estimates
Oct 31, 2025$1.86est $1.78+4.2%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:23:32 ET
24-1025-0125-0425-0725-1026-0226-0426-070.003.65
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$17.0B+10.2%
2026-03-31$15.0B–
2025-12-31$16.6B–
2025-09-30$15.8B–
2025-06-30$15.4B–

Recent dividends

2026-10-15: $1.730 · 2026-07-15: $1.730 · 2026-04-15: $1.730 · 2026-01-16: $1.730 · 2025-10-15: $1.640 · 2025-07-15: $1.640 · 2025-04-15: $1.640 · 2025-01-15: $1.640

News & catalysts

More news
Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different
24/7 Wall St. · Oct 23
AbbVie shares may move 5% on Oct. 30 earnings release
Investing.com · Oct 23
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer
Nasdaq · Oct 22
Great News for AbbVie Stock Investors
Nasdaq · Oct 22
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
MarketBeat · Oct 21
Rating changes
Reiterated
2026-10-23 · Goldman Sachs reiterated Neutral on ABBV
Reiterated
2026-10-21 · Barclays reiterated Overweight on ABBV
Reiterated
2026-10-13 · RBC Capital reiterated Outperform on ABBV
Reiterated
2026-10-09 · UBS reiterated Neutral on ABBV
Reiterated
2026-10-09 · Guggenheim reiterated Buy on ABBV
Reiterated
2026-10-08 · JP Morgan reiterated Overweight on ABBV

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER · 2026-08-14
Sell
$8.2M
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-27 18:23:32 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026